REGENXBIO is the lead sponsor of 7 current clinical trials in our USA, Brazil and Canada registers. None of its ClinicalTrials.gov trials is recruiting at the moment. The most common phase is Observational. The most-studied condition is Duchenne Muscular Dystrophy.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Long Term Follow-Up for RGX-111
NCT06103487 · Mucopolysaccharidosis I
|
Observational | By invitation | 2023-07 | USA, Brazil |
|
Long Term Follow-up for RGX-202
NCT06491927 · ClinicalTrials.gov ↗ · Duchenne Muscular Dystrophy
|
Observational | By invitation | 2024-05 | USA |
|
CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)
NCT03566043 · ClinicalTrials.gov ↗ · Mucopolysaccharidosis Type II (MPS II)
|
Phase 2/3 | Active, closed | 2018-09 | USA, Brazil |
|
AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD
NCT05683379 · Duchenne Muscular Dystrophy
|
Observational | Active, closed | 2022-12 | USA |
|
RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)
NCT07236606 · MPS II, Hunter Syndrome (MPS II)
|
Phase 3 | Active, closed | 2025-11 | USA |
|
Long-term Follow-Up for RGX-121
NCT04597385 · ClinicalTrials.gov ↗ · Mucopolysaccharidosis II
|
Observational | Active, closed | 2021-03 | USA, Brazil |
|
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
NCT05693142 · ClinicalTrials.gov ↗ · Duchenne Muscular Dystrophy
|
Phase 2/3 | Active, closed | 2023-01 | USA, Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 7 | 0 |
| Clinical trials in Brazil | 3 | 0 |
| Clinical trials in Canada | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| Sarepta Therapeutics | 6 |
| Italfarmaco | 3 |
| Solid Biosciences | 3 |
| NS Pharma | 3 |
| Lokman Hekim University | 3 |
| Edgewise Therapeutics | 2 |
| Wave Life Sciences USA | 2 |
| Genethon | 1 |
Sponsors with the most current trials registered for this condition.
REGENXBIO is the lead sponsor of 7 current trials on ClinicalTrials.gov in our USA, Brazil and Canada registers, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of its 7 ClinicalTrials.gov trials is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.